Alberto Ballestrero
Overview
Explore the profile of Alberto Ballestrero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
2442
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ravera F, Dameri M, Nuzzo P, Stabile M, Fregatti P, Ballestrero A, et al.
J Liq Biopsy
. 2025 Mar;
6:100159.
PMID: 40027300
The potential of cell-free DNA (cfDNA) methylation profiling in oncology is increasingly recognized for its ability to offer a comprehensive assessment of tumor biology. In this report, we explore the...
2.
Ceccardi A, Dameri M, Ravera F, Gilardi N, Stabile M, Lombardo I, et al.
Br J Haematol
. 2025 Jan;
206(2):758-762.
PMID: 39814683
No abstract available.
3.
Parisi F, De Luca G, Mosconi M, Lastraioli S, Dellepiane C, Rossi G, et al.
Cancer Treat Res Commun
. 2024 Sep;
41:100839.
PMID: 39217684
Background: Molecular characterization is pivotal for managing non-small cell lung cancer (NSCLC), although this process is often time-consuming and patients' conditions might worsen while molecular analyses are processed. Our primary...
4.
Pinto C, Orlandi A, Normanno N, Maiello E, Calegari M, Antonuzzo L, et al.
J Clin Oncol
. 2024 Jan;
42(11):1278-1287.
PMID: 38181312
Purpose: The intensity of anti-EGFR-based first-line therapy for wild-type (wt) metastatic colorectal cancer (mCRC), once disease control is achieved, is controversial. A de-escalation strategy with anti-EGFR monotherapy represents a potential...
5.
Vallome G, Cafaro I, Bottini A, Dellepiane C, Rossi G, Bennicelli E, et al.
Heliyon
. 2023 Nov;
9(11):e21177.
PMID: 37928020
Background: Lung cancer patients diagnosed following emergency admission often present with advanced disease and poor performance status, leading to suboptimal treatment options and outcomes. This study aimed to investigate the...
6.
Dameri M, Garlaschi A, Cuccarolo P, Ceccardi A, Stabile M, Valente I, et al.
Tumori
. 2023 Jun;
109(6):NP14-NP20.
PMID: 37265183
Multiple myeloma is a hematological cancer characterized by relapse after treatment and poor prognosis. Ixazomib, a second-generation protease inhibitor, is one of the most recently available treatments for relapsed or...
7.
Roelands J, Kuppen P, Ahmed E, Mall R, Masoodi T, Singh P, et al.
Nat Med
. 2023 May;
29(5):1273-1286.
PMID: 37202560
The lack of multi-omics cancer datasets with extensive follow-up information hinders the identification of accurate biomarkers of clinical outcome. In this cohort study, we performed comprehensive genomic analyses on fresh-frozen...
8.
Dameri M, Cirmena G, Ravera F, Ferrando L, Cuccarolo P, Stabile M, et al.
Crit Rev Oncol Hematol
. 2023 Mar;
185:103963.
PMID: 36931614
Liquid biopsy has the potential to drastically change clinical practice, paving the way to a novel non-invasive approach for cancer diagnosis and treatment. One of the limitations for the implementation...
9.
Lambertini M, Ceppi M, Anderson R, Cameron D, Bruzzone M, Franzoi M, et al.
J Natl Compr Canc Netw
. 2023 Jan;
21(1):33-41.e16.
PMID: 36634607
Background: The potential gonadotoxicity of anti-HER2 agents remains largely unknown, and limited, conflicting evidence exists for taxanes. Antimüllerian hormone (AMH) is an established biomarker of ovarian reserve that may aid...
10.
Ferrando L, Vingiani A, Garuti A, Vernieri C, Belfiore A, Agnelli L, et al.
PLoS Genet
. 2023 Jan;
19(1):e1010563.
PMID: 36595552
Background: Previous studies have provided a comprehensive picture of genomic alterations in primary and metastatic Hormone Receptor (HR)-positive, Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer (HR+ HER2- BC)....